Ustekinumab

Identification

Summary

Ustekinumab is a targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis.

Brand Names
Stelara
Generic Name
Ustekinumab
DrugBank Accession Number
DB05679
Background

Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses.2 It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice.2 It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways.1

The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis, alone or in combination with methotrexate. In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients. In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. Ustekinumab is currently the first and only approved biologic therapy for ulcerative colitis that targets the interleukin (IL)-12 and IL-23 cytokines.8 The dosing regimen for ustekinumab is based on the patient's weight and there are intravenous and subcutaneous formulations of the drug based on the dosing schedule and condition being treated. Ustekinumab is commonly marketed under the trade name STELARA.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Structure
Db05679
Protein Chemical Formula
Not Available
Protein Average Weight
148600.0 Da (approximate)
Sequences
>Ustekinumab heavy chain
EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRY
SPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSSS
STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTH
References:
  1. USTEKINUMAB FAB HEAVY CHAIN in PDB entry 3hmx [Link]
>Ustekinumab light chain
DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPEKAPKSLIYAASSLQSGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPYTFGQGTKLEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
References:
  1. USTEKINUMAB FAB LIGHT CHAIN in PDB entry 3hmx [Link]
Download FASTA Format
Synonyms
  • Stelera
  • Ustekinumab
External IDs
  • CNTO 1275
  • CNTO-1275
  • CNTO1275
  • L04AC05
  • TT 20
  • TT-20
  • TT20

Pharmacology

Indication

Ustekinumab is indicated for the management of moderate to severe plaque psoriasis in children aged 6 and above, adolescents, and adults who are candidates for phototherapy or systemic therapy.6,7

It is indicated for the management of active psoriatic arthritis in adults, alone or in combination with methotrexate.6

It is indicated for the management of moderately to severely active Crohn’s disease in adults who were clinically unresponsive or intolerant to immunomodulator or corticosteroid therapy (but never failed a tutor necrosis factor (TNF) blocker) or treatment with one or more TNF blockers.6

It is indicated for the management of moderately to severely active ulcerative colitis in adults.7

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Ustekinumab is a targeted antibody therapy that suppresses immune responses. It acts by reducing the signaling pathways of pro-inflammatory cytokines IL-12 and IL-23, which play a role in various inflammatory conditions.7 It downregulates the gene expression of inflammatory cytokines and chemokines such as MCP-1, TNF-alpha, IP-10, and IL-8.9 The formation of cytochrome P-450 enzymes may be altered by elevated levels of certain cytokines during chronic inflammation.6 Research shows that there is an inverse relationship between plasma levels of inflammatory cytokines and CYP450 enzyme formation and activity. While ustekinumab may potentially normalize the formation of CYP enzymes and enhance the CYP-mediated metabolism of drugs,5 there were no clinically significant effects on human CYP enzyme activities.7 The steady-state was achieved by 28 weeks after multiple subcutaneous dose administration in adult patients with psoriasis.7

Mechanism of action

Interleukin (IL)-12 and IL-23 are heterodimeric cytokines that evoke immune and inflammatory responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation.6,7 The role of IL-12 and IL-23 were implicated in a variety of chronic inflammatory conditions, such as psoriasis and inflammatory bowel diseases. They modulate lymphocyte function, including T-helper (Th) 1 and Th17 cell subsets,2 as CD4+ T cells can differentiate into T-helper (Th) effector lineages based on the environment. Th cells can further activate the downstream pro-inflammatory mediators and transcription factors such as TNFα and IFNγ that drive innate and adaptive immunity.4

IL-12 and IL-23 share a common p40 subunit, paired with p35 and p19 subunits of IL-12 and IL-23, respectively. 4 The antigen-binding fragment (Fab) of ustekinumab binds the D1 domain of the p40 subunit of IL-12 and IL-23 in a 1:1 ratio.4 This prevents IL-12 and IL-23 from binding to the IL-12Rβ1 receptor chain of IL-12 (IL-12Rβ1/β2) and IL-23 (IL-12Rβ1/23R) receptor complexes on the surface of NK and T cells.2 Ustekinumab only binds to IL-12 and IL-23 that are unbound to IL-12Rβ1,9 so it is unlikely to initiate Fc effector functions, such as ADCC or CDC.2 Inhibition of the IL-12/23 signalling pathway leads to profound suppression of both the Th1 and Th17 cell lineage of cytokines and chemokines and their inflammatory pathways.3

TargetActionsOrganism
AInterleukin-12 subunit beta
inhibitor
Humans
AInterleukin-23
inhibitor
Humans
Absorption

The median Tmax following a single subcutaneous dose administration of 45mg and 90mg in adults with psoriasis was 13.5 days and 7 days, respectively. The median Cmax in the same group of patients was 2.4 μg/mL and 5.3 μg/mL at doses of 45mg and 90mg, respectively. The median AUC was 84.9 μg·day/mL and 226.9 μg·day/mL, respectively.9 Following an intravenous induction dose administration, the mean ± SD Cmax was 125.2 ± 33.6 mcg/mL in patients with Crohn’s disease and 129.1 ± 27.6 mcg/mL in patients with ulcerative colitis.7

The systemic exposure of ustekinumab (Cmax and AUC) increases in a linear or dose-proportional manner following a single subcutaneous administration at doses ranging from approximately 24 mg to 240 mg in patients with psoriasis. The estimated absolute bioavailability (F) of ustekinumab following a single subcutaneous dose administration in patients with psoriasis is 57.2%.9

Volume of distribution

The total volume of distribution at steady-state was 4.62 L in patients with Crohn’s disease and 4.4 L in patients with ulcerative colitis.7 The median apparent volume of distribution during the terminal phase (Vz/F) ranged from 76 to 161 mL/kg in patients with psoriasis receiving a single subcutaneous dose.9

Protein binding

There is no information on plasma protein binding of ustekinumab.

Metabolism

The metabolic pathway of ustekinumab has not been fully characterized; it is expected to undergo nonspecific protein degradation via catabolic pathways in the same manner as endogenous IgG.6,7

Route of elimination

There is limited information on the main route of elimination of ustekinumab; it is expected to undergo renal excretion following degradation.

Half-life

Following administration of a single subcutaneous dose of 45 mg or 90 mg in patients with psoriasis, the median half-life was 19.8 days and 21.2, respectively.9 The estimated median terminal half-life of approximately 19 days in patients with Crohn’s disease or ulcerative colitis.6,7

Clearance

The median apparent clearance (CL/F) following a single subcutaneous administration to patients with psoriasis ranged from 2.7 to 5.3 mL/day/kg.9 In patients with Crohn’s disease, the clearance was 0.19 L/day in patients with Crohn’s disease or ulcerative colitis.6,7

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Signs of dose-limiting toxicity were not observed with intravenous administration of single doses up to 6 mg/kg in clinical trials. Information on overdose of ustekinumab is limited: in the event of overdose, patients should be monitored for any signs and symptoms of drug-related adverse events and appropriate symptomatic treatment should be initiated.6,7

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Ustekinumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Ustekinumab.
AducanumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ustekinumab.
AlirocumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Alirocumab.
AmivantamabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Anifrolumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Ustekinumab is combined with Antilymphocyte immunoglobulin (horse).
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
StelaraInjection, solution90 mgSubcutaneousJanssen Cilag International Nv2016-09-08Not applicableEU flag
StelaraSolution130 mg/26mLIntravenousJanssen Biotech, Inc.2016-09-23Not applicableUS flag
StelaraSolution90 mg / 1.0 mLSubcutaneousJanssen Pharmaceuticals2013-01-07Not applicableCanada flag
StelaraInjection, solution90 mgSubcutaneousJanssen Cilag International Nv2016-09-08Not applicableEU flag
StelaraInjection, solution90 mg/1mLSubcutaneousJanssen Biotech, Inc.2009-09-25Not applicableUS flag
StelaraSolution45 mg / 0.5 mLSubcutaneousJanssen Pharmaceuticals2009-01-05Not applicableCanada flag
StelaraInjection, solution45 mgSubcutaneousJanssen Cilag International Nv2016-09-08Not applicableEU flag
StelaraInjection, solution45 mgSubcutaneousJanssen Cilag International Nv2016-09-08Not applicableEU flag
StelaraSolution5 mg / mLIntravenousJanssen Pharmaceuticals2016-12-21Not applicableCanada flag
StelaraInjection, solution, concentrate130 mgIntravenousJanssen Cilag International Nv2020-12-16Not applicableEU flag

Categories

ATC Codes
L04AC05 — Ustekinumab
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
FU77B4U5Z0
CAS number
815610-63-0

References

General References
  1. Thibodaux RJ, Triche MW, Espinoza LR: Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review. Expert Opin Biol Ther. 2018 Jul;18(7):821-827. doi: 10.1080/14712598.2018.1492545. Epub 2018 Jul 9. [Article]
  2. Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles-Komar JM, Mascelli MA: Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011 Nov-Dec;3(6):535-45. doi: 10.4161/mabs.3.6.17815. Epub 2011 Nov 1. [Article]
  3. Koutruba N, Emer J, Lebwohl M: Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Ther Clin Risk Manag. 2010 Apr 15;6:123-41. doi: 10.2147/tcrm.s5599. [Article]
  4. Luo J, Wu SJ, Lacy ER, Orlovsky Y, Baker A, Teplyakov A, Obmolova G, Heavner GA, Richter HT, Benson J: Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol. 2010 Oct 8;402(5):797-812. doi: 10.1016/j.jmb.2010.07.046. Epub 2010 Aug 4. [Article]
  5. Frye RF, Schneider VM, Frye CS, Feldman AM: Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail. 2002 Oct;8(5):315-9. [Article]
  6. STELARA® (ustekinumab) injection - FDA Label [Link]
  7. STELARA® (ustekinumab) injection -Janssen Full Prescribing Information [Link]
  8. Janssen Announces FDA Approval of Stelara (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis [Link]
  9. STELARA® (ustekinumab) Product Monograph - Janssen Inc. [Link]
KEGG Drug
D09214
PubChem Substance
347910190
RxNav
847083
ChEMBL
CHEMBL1201835
Drugs.com
Drugs.com Drug Page
Wikipedia
Ustekinumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentCardiovascular Disease (CVD) / Psoriasis (PsO)1
4CompletedTreatmentPsoriasis (PsO)2
4Not Yet RecruitingBasic ScienceInflammatory Bowel Diseases (IBD) / Psoriasis (PsO)1
4Not Yet RecruitingTreatmentCrohn's Disease (CD)2
4RecruitingTreatmentCongenital Ichthyosis1
4RecruitingTreatmentCrohn's Disease (CD)1
4RecruitingTreatmentCrohn's Disease (CD) / Inflammatory Bowel Diseases (IBD) / Ulcerative Colitis1
4RecruitingTreatmentPsoriasis (PsO)1
4Unknown StatusTreatmentPsoriasis Vulgaris (Plaque Psoriasis) / Scalp Psoriasis1
4Unknown StatusTreatmentPsoriasis With Cell-derived Microparticles1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
InjectionSubcutaneous
Injection, solutionIntravenous; Subcutaneous45 MG
Injection, solutionIntravenous; Subcutaneous90 MG
Injection, solutionSubcutaneous45 mg
Injection, solutionSubcutaneous45 mg/0.5mL
Injection, solutionSubcutaneous90 mg
Injection, solutionSubcutaneous90 mg/1mL
Injection, solution, concentrateIntravenous130 mg
Injection, solution, concentrateIntravenous; Parenteral130 MG
SolutionIntravenous130 mg/26mL
SolutionIntravenous5 mg / mL
SolutionSubcutaneous45 mg / 0.5 mL
SolutionSubcutaneous90 mg / 1.0 mL
Injection, solution, concentrateIntravenous130 mg/26ml
Injection, solution, concentrate
Injection, solution, concentrateIntravenous
Injection, solution
Injection, solutionSubcutaneous
SolutionSubcutaneous45 mg
SolutionSubcutaneous90 mg
Injection, solution90 mg/1ml
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein heterodimerization activity
Specific Function
Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC....
Gene Name
IL12B
Uniprot ID
P29460
Uniprot Name
Interleukin-12 subunit beta
Molecular Weight
37168.645 Da
References
  1. Reddy M, Davis C, Wong J, Marsters P, Pendley C, Prabhakar U: Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. Cell Immunol. 2007 May;247(1):1-11. Epub 2007 Aug 29. [Article]
  2. Wittig BM: Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases. Curr Opin Investig Drugs. 2007 Nov;8(11):947-54. [Article]
Kind
Protein group
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Protein heterodimerization activity
Specific Function
Cytokine that can act as a growth factor for activated T and NK cells, enhance the lytic activity of NK/lymphokine-activated killer cells, and stimulate the production of IFN-gamma by resting PBMC....

Components:
References
  1. Engel T, Kopylov U: Ustekinumab in Crohn's disease: evidence to date and place in therapy. Ther Adv Chronic Dis. 2016 Jul;7(4):208-14. doi: 10.1177/2040622316653306. Epub 2016 Jul 6. [Article]
  2. Khanna R, Chande N, Vermeire S, Sandborn WJ, Parker CE, Feagan BG: The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews. Inflamm Bowel Dis. 2016 Jul;22(7):1737-43. doi: 10.1097/MIB.0000000000000808. [Article]

Drug created on November 18, 2007 18:26 / Updated on September 27, 2021 07:54